Resumo

HERRERA-GARCIA, José Carlos; ARELLANO-MONTELLANO, Ek Ixel; JARAMILLO-ARELLANO, Luis Enrique  e  ESPINOZA-ARELLANO, Andrea. Successful use of omalizumab in patients with overlap syndrome asthma-COPD in a University Hospital of Puebla. Med. interna Méx. [online]. 2019, vol.35, n.2, pp.298-301.  Epub 30-Set-2020. ISSN 0186-4866.  https://doi.org/10.24245/mim.v35i2.2090.

The term asthma/COPD, called SOAE (overlap asthma/EPOC acronym in English ACOS [asthma COPD overlap syndrome]), includes a subset of patients with persistence and airflow limitation that presents clinical features of both asthma and COPD. Lack of consensus on a definition of ACOS has led to the wide range in prevalence ranging between 11 and 56% in COPD, 13 and 61% in asthma, and 2% in the general population. The initial studies have shown that omalizumab may be useful in patients with ACOS, it has been shown to improve symptoms, reduce exacerbations and hospitalization, as well as improve lung function parameters and reduce steroid requirement in these patients. This paper describes the effect of omalizumab in 5 patients with a diagnosis of overlying asthma/COPD syndrome (SOAE) and administration of omalizumab. We describe the experience of our center and the benefits that the treatment has given to our patients. These benefits have allowed the patient a better quality of life and radically reduce their morbidity.

Palavras-chave : Asthma; COPD; Omalizumab.